# A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.

> **NCT07058662** · PHASE1,PHASE2 · RECRUITING · sponsor: **Belief BioMed (Beijing) Co., Ltd** · enrollment: 9 (estimated)

## Conditions studied

- DMD

## Interventions

- **GENETIC:** Single dose intravenous of BBM-D101

## Key facts

- **NCT ID:** NCT07058662
- **Lead sponsor:** Belief BioMed (Beijing) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-31
- **Primary completion:** 2027-06-30
- **Final completion:** 2031-06-30
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2025-12-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07058662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07058662, "A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07058662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*